RxDoctor Payments Data

Muhammad Zakaria, MD

Internal Medicine · Brooklyn, NYNPI 1447269824

Payments from drug & device makers

$716in general payments, 2019–2025

Across 7 payments — averaging $102.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$375
  • SK Life Science, Inc.$125
  • Sanofi$122
  • AbbVie$95

What the payments were for

  • Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mannkind Corporation4$375
SK Life Science, Inc.1$125
Sanofi1$122
AbbVie1$95

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$716 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$401,082
Medicare patients
521
Services billed
4,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate421$181,602
BiktarvyBictegrav/Emtricit/Tenofov Ala35$159,948
JardianceEmpagliflozin234$105,579
EliquisApixaban224$91,370
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf16$80,191
NuplazidPimavanserin Tartrate19$64,270
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$46,384
EntrestoSacubitril/Valsartan114$40,152
XareltoRivaroxaban116$39,668
AfrezzaInsulin Regular, Human15$39,185
OrgovyxRelugolix23$33,771
DescovyEmtricitabine/Tenofov Alafenam13$30,288
MounjaroTirzepatide23$29,040
OzempicSemaglutide23$28,944
FarxigaDapagliflozin Propanediol41$27,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mannkind CorporationAfrezza$375$39,18515 claims
AbbVieLinzess, Alphagan P$95$27,62860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →